Cargando…

Phenotype of BTK‐lacking myeloid cells during prolonged COVID‐19 and upon convalescent plasma

XLA patient with 7‐month course of COVID‐19 with persistent plasma SARS‐CoV‐2 load revealed a sustained non‐inflammatory profile of myeloid cells in association with contained severity of disease, arguing in favor of the use of BTK inhibitors in SARS‐COV‐2 infection.

Detalles Bibliográficos
Autores principales:	Gomes, André M. C., Farias, Guilherme B., Trombetta, Amelia C., Godinho‐Santos, Ana, Parreira, Inês, Gonçalves, Hélder Diogo, Simões, Mariana Lessa, Aguiar, Patrício, Deveza, Maria Manuel, Inácio, João, Sousa, Ana E., da Silva, Susana Lopes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9874515/ https://www.ncbi.nlm.nih.gov/pubmed/36208028 http://dx.doi.org/10.1111/ejh.13881

Ejemplares similares

Therapeutic Notes upon Convalescence
Publicado: (1887)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
por: Kueffer, Lauren E., et al.
Publicado: (2021)

Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors
por: Qi, Jialei, et al.
Publicado: (2023)

Severe B Cell Deficiency in Mice Lacking the Tec Kinase Family Members Tec and Btk
por: Ellmeier, Wilfried, et al.
Publicado: (2000)

Headache as the sole presentation of cerebral venous thrombosis: a prospective study
por: Timóteo, Ângela, et al.
Publicado: (2012)

Differential impact of BTK active site inhibitors on the conformational state of full-length BTK
por: Joseph, Raji E, et al.
Publicado: (2020)

Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma
por: Jiang, Vivian Changying, et al.
Publicado: (2023)

Progressive Multifocal Leukoencephalopathy in a Chemotherapy-Naive Patient With Chronic Lymphocytic Leukemia: A Case Report
por: Jancar, Nina, et al.
Publicado: (2022)

Detection of Low-Copy Human Virus DNA upon Prolonged Formalin Fixation
por: Mielonen, Outi I., et al.
Publicado: (2022)

BTK: sensing pathogenic nucleic acids
por: Lee, Koon-Guan, et al.
Publicado: (2015)

A Fast and Clean BTK Inhibitor
por: Gabizon, Ronen, et al.
Publicado: (2020)

The race to stymie BTK: zanu zings
por: Kapoor, Prashant, et al.
Publicado: (2020)

Targeting Solid Tumors With BTK Inhibitors
por: Uckun, Fatih M., et al.
Publicado: (2021)

BTK, the new kid on the (oncology) block?
por: Grassilli, Emanuela, et al.
Publicado: (2022)

Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)

The lack of BTK does not impair monocytes and polymorphonuclear cells functions in X-linked agammaglobulinemia under treatment with intravenous immunoglobulin replacement
por: Cavaliere, Filomena Monica, et al.
Publicado: (2017)

A mutation in the promoter region of BTK causes atypical XLA
por: Bravo García-Morato, María, et al.
Publicado: (2020)

BTK mutations selectively regulate BTK expression and upregulate monocyte XBP1 mRNA in XLA patients
por: Teocchi, Marcelo A, et al.
Publicado: (2015)

Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance
por: Naeem, Aishath, et al.
Publicado: (2022)

Lack of Melanopsin Is Associated with Extreme Weight Loss in Mice upon Dietary Challenge
por: Aytürk, Didem Göz, et al.
Publicado: (2015)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI
por: Nicolson, Phillip L.R., et al.
Publicado: (2018)

Discovery of a potent BTK and IKZF1/3 triple degrader through reversible covalent BTK PROTAC development
por: Yu, Xin, et al.
Publicado: (2022)

PB1912: BTK AND PLCG2 GENE MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS WITH RESISTANCE TO COVALENT BTK INHIBITOR
por: Likold, Ekaterina, et al.
Publicado: (2023)

Differential Evolutionary Wiring of the Tyrosine Kinase Btk
por: Nawaz, Hossain M., et al.
Publicado: (2012)

Ibrutinib and novel BTK inhibitors in clinical development
por: Akinleye, Akintunde, et al.
Publicado: (2013)

Btk Regulates Macrophage Polarization in Response to Lipopolysaccharide
por: Ní Gabhann, Joan, et al.
Publicado: (2014)

Effects of BTK signalling in pathogenic microorganism infections
por: Ye, Bingjue, et al.
Publicado: (2019)

Low-dose Btk inhibitors: an ‘aspirin’ of tomorrow?
por: Payrastre, Bernard, et al.
Publicado: (2021)

Targeting the NLRP3 Inflammasome via BTK
por: Weber, Alexander N. R.
Publicado: (2021)

Current and novel BTK inhibitors in Waldenström’s macroglobulinemia
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2021)

Integrin Signaling Shaping BTK-Inhibitor Resistance
por: Polcik, Laura, et al.
Publicado: (2022)

The Evil Effect upon Women of Prolonged Standing
Publicado: (1899)

Early ART in Acute HIV-1 Infection: Impact on the B-Cell Compartment
por: Badura, Robert, et al.
Publicado: (2020)

Acute HIV-1 and SARS-CoV-2 Infections Share Slan+ Monocyte Depletion—Evidence from an Hyperacute HIV-1 Case Report
por: Farias, Guilherme B., et al.
Publicado: (2021)

From identification of the BTK kinase to effective management of leukemia
por: Smith, C I E
Publicado: (2017)

The Development of BTK Inhibitors: A Five-Year Update
por: Tasso, Bruno, et al.
Publicado: (2021)

BTK Inhibitors Impair Platelet-Mediated Antifungal Activity
por: Nasillo, Vincenzo, et al.
Publicado: (2022)

The Immunomodulatory Functions of BTK Inhibition in the Central Nervous System
por: Cao, Tingyu, et al.
Publicado: (2022)

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_lle1o8v4a09pe1goqdu62p1278